Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omal...

Descripción completa

Detalles Bibliográficos
Autores principales: Metz, Martin, Staubach, Petra, Bauer, Andrea, Brehler, Randolf, Gericke, Janine, Kangas, Michael, Ashton-Chess, Joanna, Jarvis, Philip, Georgiou, Panayiotis, Canvin, Janice, Hillenbrand, Rainer, Erpenbeck, Veit J., Maurer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399592/
https://www.ncbi.nlm.nih.gov/pubmed/28435464
http://dx.doi.org/10.7150/thno.18304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399592/
https://www.ncbi.nlm.nih.gov/pubmed/28435464
http://dx.doi.org/10.7150/thno.18304

Ejemplares similares